Public Interest Capital: George Hara’s Blueprint for Scaling Technology, Biotech, and the Middle Class

At a time when global capital is increasingly measured by short-term returns and rapid exits, DEFTA Partners Group Chairman and CEO George Hara offered a different framework: build industries that generate both profit and societal stability. Speaking to an audience of entrepreneurs, investors, and business leaders, Hara framed the core mission of modern capitalism in simple terms — make money, and contribute to society, simultaneously.

If done correctly, he argued, the result is not only financial success, but the reconstruction of a healthy middle class through technology-led economic growth.

The Structural Problem: Capital Chasing Speed Over Substance

Hara began by identifying what he sees as one of the world’s most pressing economic risks: the widening gap between rich and poor. In his view, the issue is not only technological disruption or globalization, but the way capital itself is deployed.

Today’s investment environment increasingly rewards short cycles. M&A-driven returns, financial engineering, and speculative capital can generate outsized internal rates of return compared to long-term R&D investment. But that efficiency comes at a cost.
When capital flows primarily toward short-term gains instead of real industrial development, the financial economy expands faster than the real economy it is meant to support.

This distinction was a recurring theme in his remarks. Investments that skip R&D and focus only on acquisition or distribution may generate faster returns on paper, but they do little to build new industries, new technologies, or durable employment structures. In contrast, funding deep science — from research to manufacturing to distribution — takes longer, but anchors real economic activity.

“A good businessman has to build the real economy, not just the financial economy,” Hara emphasized.

The imbalance, he noted, contributes to asset bubbles and wealth concentration, where middle-class value creation is gradually absorbed by speculative cycles rather than productive industries.

Rebuilding the Middle Class Through Technology Industries

For Hara, the solution is not anti-capitalist — it is structural.
Countries that successfully built strong middle classes, including Japan, Taiwan, and the United States during their industrial growth phases, did so by investing in technology sectors that created skilled employment, long-term productivity, and industrial ecosystems.

In practical terms, this means supporting sectors such as biotech, informatics, cybersecurity, and advanced medical technologies — industries he himself has helped build from early stages. These sectors require engineers, researchers, regulatory specialists, manufacturing teams, and clinical operators, creating layered employment rather than isolated financial gains.

Technology industries, particularly deep-tech and biotech, function as multipliers:

• They create high-skill jobs
• They generate supply chains
• They anchor regional innovation hubs
• They produce long-term societal value beyond financial returns

Without these sectors, economic growth becomes concentrated rather than distributed.

Public Interest Capital: A Stakeholder-Based Model

Central to Hara’s thesis is what he calls “public interest capital” — a framework that redefines how profits and value should be distributed within an innovation-driven economy.

Instead of prioritizing shareholders alone, he argues that corporate success is built collectively by:

• Employees — the scientists running R&D programs, engineers scaling production systems, and clinical teams executing trials that transform discovery into real-world products.
• Customers — hospitals, physicians, and patients who adopt new therapies or technologies and validate their effectiveness in practice.
• Suppliers — manufacturers, reagent providers, semiconductor and device supply chains that enable production, quality control, and scale.
• Regional Communities — local ecosystems that benefit from job creation, research clusters, infrastructure development, and sustained economic activity around labs and manufacturing sites.
• Long-Term Investors — providers of patient capital who support years of negative cash flow typical in biotech and deep-tech development cycles.
• Society at Large — the broader public framework that makes innovation possible, including education systems, regulatory structures, public infrastructure, environmental resources, and civic stability.

In real terms, these stakeholders are not abstract categories but operational contributors to value creation.

“If a company generates profit, it exists because many stakeholders contributed,” he said. “Fair distribution of value is essential.”

This philosophy stands in contrast to short-term shareholder primacy. In practice, Hara argues that profit-sharing mechanisms, employee equity, and reinvestment into R&D ecosystems create more durable and sustainable economic growth than purely extractive financial returns.

Long-Term Vision Over Quarterly Performance

Hara also criticized the increasing dominance of quarterly performance metrics in public markets, arguing that they discourage deep innovation.
Biotech, advanced manufacturing, and frontier technologies require extended development cycles, often involving years of negative cash flow before commercialization.

This aligns closely with his remarks on investment timelines: a one-year financial gain may show high IRR, but it is closer to speculative capital than true industrial investment. By contrast, companies that invest from research through manufacturing and distribution over a decade generate lower short-term returns but stronger real economic impact.

Short-term evaluation frameworks, he suggested, misalign investor expectations with scientific reality.

His policy advocacy reflects this belief. As an advisor to Japanese leadership, he previously supported reforms aimed at reducing excessive quarterly pressure in corporate governance to encourage long-term research and development.

Deep Science Needs Patient Capital and Strategic Alliances

Drawing from his experience building companies across the U.S., Europe, Israel, and Asia, Hara emphasized that deep science commercialization is inherently capital-intensive and operationally complex.
Early-stage ventures often generate negative cash flow during R&D, clinical validation, and regulatory preparation — a phase where many promising technologies fail due to funding gaps rather than scientific weakness.

In the transcript, he highlighted how alliances with large institutions and professors are essential not just for invention, but for execution. Academic inventors may understand breakthrough science but lack expertise in manufacturing scale-up, quality assurance, regulatory navigation, and global distribution.

His approach highlights three operational principles:

• Understanding deep science timelines
• Maintaining long-term investment patience
• Forming strategic alliances with large institutions and industry partners

In reality, this could mean venture funds co-building companies with university labs, partnering with large medical device firms for manufacturing, or aligning with hospitals for clinical validation rather than forcing premature commercialization.

Entrepreneurship as a Cultural Imperative

Another risk Hara identified is the tendency for successful investors and corporations to become conservative over time.
Wealth accumulation, he argued, can reduce willingness to take risks on uncertain but transformative technologies.

This is especially visible in deep-tech sectors where returns are delayed. Investors trained in business-school models may prioritize exit timelines or IPO targets rather than product quality, whereas Hara explicitly noted that the objective should not be IPO first, but building a good product and making employees prosperous as a result.

Sustained industrial growth requires continuous entrepreneurial reinvestment into new sectors — even when outcomes are uncertain.
“Challenge is very important,” he said, stressing that innovation ecosystems stagnate when capital prioritizes safety over experimentation.

Asia’s Emerging Role in Cross-Border Innovation

Hara also pointed to the growing importance of cross-border technology ecosystems, particularly in Asia.
With global universities and research institutions increasingly establishing laboratories in regional hubs such as Hong Kong, the geography of innovation is becoming more distributed rather than concentrated in a single Western center.

From a practical standpoint, this reflects a shift toward joint ventures between venture capital, universities, and regional research ecosystems — a model he described as already underway through collaborations with major global academic institutions.

Rather than a single dominant center, the future innovation model may involve:

• Research anchored in top academic institutions
• Venture formation through regional partnerships
• Global scaling through integrated capital networks

This aligns with broader trends in biotech, where distributed development, strategic alliances, and cross-border capital flows are becoming the default operating system.

The Strategic Conclusion: Profit With Societal Alignment

Hara concluded with three pillars that define public interest capital:

1. Fair distribution of value among stakeholders
2. Long-term management perspective
3. Continuous entrepreneurial risk-taking

Taken together, the framework reframes venture building not as a short-term financial exercise, but as a mechanism for strengthening economic resilience and social stability.

In an era dominated by speculative capital cycles and compressed investment timelines, his message was clear: sustainable wealth creation comes from building real industries — especially technology and biotech — that generate long-term value for both markets and society.

For investors and policymakers alike, the implication is direct. Scaling innovation is not only about faster capital deployment, but about aligning capital, science, and societal impact over the long term.

Author

Bernice Lottering